Tissue Regenix announces appointment of David Cocke as its chief financial officer with immediate ef
Tissue Regenix PLC (LON:TRX), the regenerative medical devices company, announced that it has appointed David Cocke as its chief financial officer (CFO) and director to the board with immediate effect.
The company noted that Cocke has over 29 years of experience in the medical device industry holding senior finance and operations positions. In 1997, he founded NuPak Medical, an ISO-certified contract manufacturer of sterile disposable medical devices, with the company turning cash flow positive in two years and growing the production volume from 50,000 to 3mln over time.
NuPak Medical was acquired by Katena Products, Inc. in 2017 and Cocke remained with the business post-acquisition until early 2021, leading the expansion to double the cleanroom capacity and assembly space on-time and on-budget.
READ: Tissue Regenix says it intends to appoint Brian Phillips and Trevor Phillips (no relation) as independent non-executive directors
It said Cocke was also chief financial officer at Aperion Biologics from 2008-2017 and supported the board in raising $21mln from venture capital and private investors. Prior to this, he was senior director for Finance and Operations at Kinetic Concepts from 1993-1996.
In a statement, Daniel Lee, the chief executive officer of Tissue Regenix commented: “David is a well-respected finance professional in the medical device industry. His experience of implementing financial systems and management as well as operations, will be invaluable to the Group as we undertake the next stages of our capacity expansion programme. Having worked with David previously at Aperion Biologics I have seen first-hand the value he brings to a business and I am happy to welcome him to the Tissue Regenix Group.”